Physician profile
Catherine S Conner
NPI 1669676227
$1,405.13
in general payments reported to CMS, 2019-2025
25 companies · $329 in 2025
The $329 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.23 · 2020: $173 · 2021: $88.19 · 2022: $110 · 2023: $285 · 2024: $326 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $366.70 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $113.52 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $106.66 | 2020-2024 | Jornay Pm |
| Cranial Technologies, INC | $92.83 | 2019-2025 | Doc Band |
| Genentech USA, INC. | $72.45 | 2020-2021 | |
| Tris Pharma INC | $71.13 | 2020-2024 | Dyanavel Xr |
| Pfizer INC. | $64.66 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $59.09 | 2019-2024 | Vaxneuvance, M-M-R II, Vaxelis |
| Glaxosmithkline, LLC. | $57.63 | 2023-2025 | Bexsero, Menveo, Pediarix |
| Shire North American Group INC | $50.32 | 2019 | |
| Krystal Biotech INC | $46.36 | 2023-2024 | Vyjuvek |
| Sanofi-Aventis U.S. LLC | $42.55 | 2025 | |
| Sanofi Pasteur INC. | $39.57 | 2023 | |
| Neos Therapeutics, LP | $34.36 | 2022-2023 | Adzenys Xr-Odt |
| Seqirus USA INC | $23.23 | 2024 | Flucelvax |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.39 | 2023 | Flumist Quadrivalent |
| Biomarin Pharmaceutical INC. | $21.11 | 2024 | Voxzogo 1.2mg |
| Collegium Pharmaceutical, INC. | $20.83 | 2025 | Jornay Pm |
| Lnhc, INC | $16.37 | 2025 | Zelsuvmi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.02 | 2025 | |
| Vertical Pharmaceuticals, LLC | $14.97 | 2020 | |
| Adlon Therapeutics L.P. | $14.50 | 2020 | |
| Sobi, INC | $14.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.93 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.